Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
American Healthcare REIT Inc. stock has reached an all-time high, touching 37.53 USD. This significant milestone reflects a remarkable 1-year change, with the stock appreciating by 130.71%. InvestingPro analysis shows the company, now valued at $5.92 billion, is trading above its Fair Value, with analyst price targets ranging from $37 to $45. The company’s impressive performance over the past year underscores a strong market sentiment and robust investor confidence, supported by 10.53% revenue growth and a healthy current ratio of 1.39. This surge in stock price highlights American Healthcare REIT’s growth trajectory and positions it favorably among its peers in the real estate investment trust sector, offering investors a 2.73% dividend yield. InvestingPro subscribers can access 10+ additional investment tips and a comprehensive Pro Research Report for deeper analysis.
In other recent news, American Healthcare REIT reported a strong financial performance for the first quarter of 2025, with revenue reaching $540.6 million. The company saw a 26% increase in normalized funds from operations (NFFO) per share compared to the previous year, despite a negative earnings per share of -$0.04. Following these results, American Healthcare REIT raised its full-year 2025 guidance for NFFO per share to between $1.58 and $1.64. Analysts have responded positively to the company’s performance, with KeyBanc raising the price target to $40.00 and maintaining an Overweight rating, while JMP Securities also increased their target to $40.00, citing the company’s robust earnings. Citi raised its price target to $37.00, highlighting positive demographic trends and demand in the healthcare property sector. The company’s Trilogy and SHOP segments contributed significantly to the growth, with notable increases in same-store net operating income. Analysts expect these factors to drive further upside to 2025 guidance and consensus estimates.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.